February 8, 2019

Biosimilar Innovation

School of Law - University of California, Irvine

Agenda

8:45am	Welcome
9:00-10:20	Panel 1: Biosimilar Patenting
	 Nicholson Price II, University of Michigan Patent Thickets in Biologic Manufacturing
	 Dan L. Burk, UC Irvine Structure and Function in Biomolecular Obviousness
10:20-10:40	Morning Break
10:40-12:00pm	Panel 2: Regulatory Perspectives
	 Michael Carrier, Rutgers University, Camden Antitrust and Biosimilars: What's New and What's Not
	 Jordan Paradise, Loyola University Chicago <i>FDA Oversight of Biosimilars</i>
12:00-1:30pm	Lunch
1:30-2:50	Panel 3: Comparative Perspectives
	 Ariel Stern, Harvard Business School The Impact of the Entry of Biosimilars: Evidence from Europe
	 Timo Minssen, University of Copenhagen The Proposed EU IP Exception for Generics & Biosimilars Exports - A Cure Worse Than the Disease?

2:50-3:10	<u>Afternoon Break</u>
3:10-4:30	Panel 4: Scouting the Path Ahead
	 Brenda Simon, Thomas Jefferson Law School Patent Eligibility of Biologic and Biosimilar Inventions: A Doctrine in Flux
	 Jacob Sherkow, New York Law School Form Follows Function: Proper Antibody Patents After Amgen v. Sanofi
4:45	Adjourn